HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Mitchell J. Magee Todd M. Dewey Tea Acuff James R. Edgerton Michael J. Mack Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Magee, M. J. Articles by Mack, M. J. Search for Related Content PubMed PubMed Citation Articles by Magee, M. J. Articles by Mack, M. J. Related Collections Coronary disease Related Article

Ann Thorac Surg 2001;72:776-781
© 2001 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Influence of diabetes on mortality and morbidity: off-pump coronary artery bypass grafting versus coronary artery bypass grafting with cardiopulmonary bypass

^a Cardiopulmonary Research Science and Technology Institute, Dallas, Texas, USA

Address reprints requests to Dr Magee, 7777 Forest Lane, Suite A323, Dallas, TX 75230
e-mail: mmagee{at}csant.com

Presented at the Forty-seventh Annual Meeting of the Southern Thoracic Surgical Association, Marco Island, FL, Nov 9–11, 2000.

	Abstract

Top Abstract Introduction Patients and methods Results Comment Discussion References

 
Background. Myocardial revascularization in diabetic patients is challenging with no established optimum treatment strategy. We reviewed our coronary artery bypass grafting experience to determine the impact of eliminating cardiopulmonary bypass on outcomes in diabetic patients relative to nondiabetic patients.

Methods. From January 1995 through December 1999, 9,965 patients, of whom 2,891 (29%) had diabetes, underwent isolated coronary artery bypass grafting. Diabetic and nondiabetic patients were further divided into groups on the basis of cardiopulmonary bypass use. Twelve percent (346 of 2,891) of diabetic patients and 12% (829 of 7,074) of nondiabetic patients underwent coronary artery bypass grafting without cardiopulmonary bypass; the remainder had coronary artery bypass grafting with cardiopulmonary bypass. Nineteen preoperative variables were compared among treatment groups by univariate analysis.

Results. Patients undergoing coronary artery bypass grafting without cardiopulmonary bypass compared with those having coronary artery bypass grafting with cardiopulmonary bypass had higher mean predicted mortalities (diabetic, 3.96% versus 3.72%, p = 0.83; nondiabetic, 3.03% versus 2.86%, p = 0.79). In nondiabetic patients, coronary artery bypass grafting without cardiopulmonary bypass provides an actual and risk-adjusted survival advantage over coronary artery bypass grafting with cardiopulmonary bypass (1.81% versus 3.44%, p = 0.0127; risk-adjusted mortality, 1.79% versus 3.61%, p = 0.007). This survival benefit of coronary artery bypass grafting without cardiopulmonary bypass was not seen in diabetic patients (2.89% versus 3.69%, p = 0.452; risk-adjusted mortality, 2.19% versus 2.98%, p = 0.42). Diabetic patients undergoing coronary artery bypass grafting without cardiopulmonary bypass had fewer complications, including decreased blood product use (34.39% versus 58.4%, p = 0.001), and reduced incidence of prolonged ventilation (6.94% versus 12.10%, p = 0.005), atrial fibrillation (15.90% versus 23.26%, p = 0.002), and renal failure requiring dialysis (0.87% versus 2.75%, p = 0.036).

Conclusions. The survival advantage in nondiabetic patients treated with coronary artery bypass grafting without cardiopulmonary bypass is not apparent in diabetic patients. Coronary artery bypass grafting without cardiopulmonary bypass in diabetic patients is nevertheless associated with a significant reduction in morbidity.

	Introduction

Top Abstract Introduction Patients and methods Results Comment Discussion References

 
Diabetes mellitus is an established risk factor for the development of coronary artery disease. Coronary artery disease is not only more prevalent in diabetic patients compared with nondiabetic patients, but also tends to be more extensive, involving multiple vessels, and rapidly progressive [1–6]. Accordingly, diabetic patients represent a large proportion of patients requiring myocardial revascularization. Unfortunately, diabetes is also a significant risk factor for adverse early and late outcomes after percutaneous and surgical revascularization [7–10]. Diabetes is associated with higher restenosis rates after angioplasty and stent placement [11–13]. Although diabetic patients typically do worse with any management approach than nondiabetic patients, studies comparing treatment options in diabetic patients have been conflicting. The Bypass Angioplasty Revascularization Investigation trial reported a survival benefit in diabetic patients treated with coronary artery bypass grafting (CABG) compared with percutaneous transluminal coronary angioplasty, whereas other studies failed to show a significant difference [6, 14–16]. The reported effects of eliminating cardiopulmonary bypass (CPB) on morbidity and mortality in patients undergoing CABG are mostly favorable, although some have been conflicting or inconclusive [17–20]. The greatest benefit derived from eliminating CPB in CABG most likely exists in a selected risk subset of patients [21–24]. With diabetic patients representing a particularly challenging group with no optimum treatment strategy established, the opportunity to improve outcomes with a contemporary therapeutic approach is evident. Therefore, we reviewed our CABG experience to determine the impact of CPB on outcomes in diabetic patients relative to nondiabetic patients.

	Patients and methods

Top Abstract Introduction Patients and methods Results Comment Discussion References

 
Patients
A retrospective review of prospective data collected in our customized Society of Thoracic Surgeons (STS) computerized cardiac surgery group practice database identified 9,965 patients who underwent isolated CABG from January 1995 through December 1999, of whom 2,891 (29%) were diabetic and 7,074 (73%) were nondiabetic. Twelve percent (346 of 2,891) of diabetic patients and 12% (829 of 7,074) of nondiabetic patients underwent CABG without CPB (off-pump CABG; OPCABG). The remaining 88% in each group had conventional CABG using CPB (CABG-CPB). Among the total diabetic population, 35.51% were being treated with insulin. Insulin-requiring diabetic patients constituted 39.83% of the diabetic OPCABG group and 34.93% of the diabetic CABG-CPB group.

Procedure selection was at the discretion of the operating surgeon and varied accordingly. No specified selection criteria were used in determining which CABG procedure, with or without CPB, individual patients would receive, although medical comorbidities considered to increase the risks of CPB were generally used to select patients for OPCABG. The CABG-CPB and OPCABG patients were contemporaneous and not sequential cohorts.

Patient data were collected and analyzed according to the STS National Cardiac Surgery Database guidelines and definitions (http://www.ctsnet.org/doc/4314). Preoperative patient data were obtained relative to cerebrovascular disease, chronic obstructive pulmonary disease, cerebrovascular accident, hypertension, morbid obesity, peripheral vascular disease, renal failure, renal failure on dialysis, sex, current smoking, unstable angina, recent myocardial infarction (MI), arrhythmias, congestive heart failure, left main coronary artery disease, New York Heart Association class IV classification, age, and left ventricular ejection fraction. Postoperative data collected and compared between groups included length of hospital stay from operation to discharge, operative mortality, blood product use, reoperation for bleeding, MI, adult respiratory distress syndrome, prolonged ventilation, renal failure, renal failure requiring dialysis, transient and permanent neurologic dysfunction, infection, and atrial fibrillation.

Statistical analysis
Patients were grouped and compared according to preoperative disease status, diabetic versus nondiabetic, and according to surgical treatment, OPCABG versus CABG-CPB. Preoperative patient characteristics, intraoperative course, and operative outcomes were collected and compared among groups using either the ² test or two-tailed Student’s t test as appropriate. Probability values less than or equal to 0.05 were considered significant.

The predicted risk of operative mortality was calculated for each patient using the STS algorithm, and mean predicted risk scores were calculated for each group for comparison.

	Results

Top Abstract Introduction Patients and methods Results Comment Discussion References

 
Preoperative characteristics that were collected and compared among treatment groups and found to be statistically significant for either diabetic patients or nondiabetic patients are shown in Table 1. The diabetic OPCAB patients as a group were older, more often female, and more likely to have renal failure and renal failure requiring dialysis when compared with diabetic CABG-CPB patients. Likewise, the nondiabetic OPCAB patients were older, more often female, and more likely to have renal failure and renal failure requiring dialysis when compared with nondiabetic CABG-CPB patients. In contrast, obesity, left main coronary artery disease, recent MI, and unstable angina were more prevalent in the diabetic CABG-CPB group compared with their OPCAB cohort. Likewise, obesity, left main coronary artery disease, recent MI, and unstable angina as well as hypertension, lung disease, and arrhythmias were more prevalent in the nondiabetic CABG-CPB group compared with their OPCAB cohort. Additional risk factors examined and found to be similar among treatment groups are shown in Table 2. Most notable were the similarities in ventricular function, heart failure, and cerebrovascular disease.

The unadjusted and risk-adjusted mean operative mortality was less in the OPCABG group compared with the CABG-CPB group. This survival benefit of OPCABG was highly significant in the nondiabetic patients (Table 3).

	Comment

Top Abstract Introduction Patients and methods Results Comment Discussion References

During the period of study, diabetic patients as a group selected for OPCABG were older, more often female, and with renal impairment in accordance with higher risk status, but less often obese and less likely to have left main coronary artery disease, recent MI, or unstable angina. These differences in risk factors trended toward a higher overall mean predicted risk for the OPCABG group, although statistically the groups were similar. In nondiabetic patients, identical disparities noted above existed between therapeutic groups, with the addition of less hypertension, chronic obstructive pulmonary disease, and preoperative arrhythmias in the OPCABG group. Again these differences yielded a higher mean predicted risk score in the OPCABG group although the groups were statistically identical.

This study did not exclude single-vessel disease. Both diabetic and nondiabetic OPCABG groups had a lower mean number of grafts per patient than their CABG-CPB cohorts (diabetic, 2.3 versus 3.5; nondiabetic, 2.2 versus 3.4, respectively). This is largely a reflection of a much higher proportion of single CABG procedures in the OPCABG groups (diabetic, 0.347 versus 0.014; nondiabetic, 0.391 versus 0.028). The similarity in predicted risk scores among treatment groups, trending toward a higher risk in the OPCABG groups, argues against this having a favorable impact on OPCABG outcomes. Fewer mean grafts per patient may reflect an OPCABG selection bias for patients who require fewer grafts. Alternatively, surgeons performing OPCABG may have a surgeon-specific propensity to perform fewer grafts independent of the selected approach or may be influenced by procedure-related technical challenges to perform fewer grafts. The limitations of this database do not allow for precise anatomic characterization of preoperative coronary artery disease and the corresponding grafts required to achieve complete revascularization. Therefore, no conclusions can be drawn from this data as to the relative completeness of revascularization among groups.

Nondiabetic patients clearly derive a significant benefit from an OPCABG approach reflected in decreased unadjusted and risk-adjusted mortality as well as decreased morbidity, including decreased blood product use, decreased incidence of adult respiratory distress syndrome and prolonged ventilation, and decreased postoperative hospital length of stay.

It is unclear why diabetic patients do not derive the same benefits from OPCABG as nondiabetic patients. There may be factors with higher prevalence in the diabetic population, such as diffuse small vessel coronary artery disease, renal insufficiency, peripheral vascular disease, or other confounding risk variables that affect these findings. The diabetic treatment groups are smaller than the nondiabetic groups and may simply not be large enough to reflect a survival benefit.

Narrowing the analysis to include only treated diabetic patients, either with oral medication or insulin, or further narrowing the comparison to include only insulin-treated diabetic patients resulted in conclusions similar to those drawn from the entire diabetic population. Likewise, adjusting for differences in risk between diabetic treatment groups by comparing mean risk-adjusted mortalities did not alter the conclusion. Diabetic OPCABG patients as a group, compared with CABG-CPB, do benefit from less blood product use, less incidence of prolonged ventilation, less incidence of postoperative renal failure requiring dialysis, and less postoperative atrial fibrillation. This was reflected in a trend toward a decreased postoperative length of hospital stay.

In conclusion, OPCABG provides a significant survival advantage in nondiabetic patients. Off-pump CABG in diabetic patients and nondiabetic patients is associated with a significant reduction in morbidity. Additional studies including larger numbers of diabetic patients or prospective randomization are needed to confirm these conclusions.

	Discussion

Top Abstract Introduction Patients and methods Results Comment Discussion References

 
DR JOSEPH C. CLEVELAND (Denver, CO): Doctor Magee, that was beautifully presented and a nice set of data. It is always even nicer when it correlates with our data. We, similar to you, found that there were more diabetics in our on-pump group that were done, and the risk factors that you displayed are almost similar to those we showed earlier this week. In addition, we have gone through our VA database with Dr Grover and have looked at the risk factors that are prevalent in the diabetic population. There are more women, more patients with renal failure requiring dialysis, et cetera, and these subsets have more comorbidities.

I only have one question for you, and that is whether you subgrouped your diabetics into those patients on oral agents versus insulin agents? Historically there are some data that suggest that patients on oral agents do less well with myocardial type events, both with myocardial infarction and with operation. Our laboratory published data some years ago at the basic science level describing differences in the way human cardiac muscle behaves in oral-dependent diabetics versus insulin-dependent diabetics. We subsequently learned that the oral agents worked by inhibiting the potassium ATP channel, which is thought to be an endogenous cardiac protector. If there is a difference between the group that was taking oral agents versus insulin agents, it could be the oral group that could be responsible for your lack of benefit. Otherwise I think this is a beautifully presented talk and very relevant, solid data.

DR MAGEE: Thank you for your comments. We did in fact look at the insulin dependence of the patients, and you can see, as it is broken down in this slide, that the total number of insulin-dependent patients was 35% of the total population. That represented about 40% of the off-pump group and about 35% of the on-pump group, which was not statistically significant. In looking at morbidity and mortality differences, it did not differ at all from the total population.

	References

Top Abstract Introduction Patients and methods Results Comment Discussion References

 

1. Krolewski A.J., Kosinski E.J., Warram J.H., et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987;59:750-755.[Medline]
2. Hamby R.I., Sherman L., Mehta J., Aintablain A. Reappraisal of the role of the diabetic state in coronary artery disease. Chest 1976;70:251-257.[Abstract/Free Full Text]
3. Nathan D.M. Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676-1685.[Free Full Text]
4. Barbash G.I., White H.D., Modan M., Van de Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy: investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol 1993;22:707-713.[Abstract]
5. Jacoby R.M., Nesto R.W. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol 1992;20:726-744.
6. Gum P.A., O’Keefe J.H., Jr, Borkon A.M., et al. Bypass surgery versus coronary angioplasty for revascularization of treated diabetic patients. Circulation 1997;96(Suppl 2):II7-II10.
7. Kip K.E., Faxon D.P., Detre K.M., Yeh W., Kelsey S.F., Currier J.W. Coronary angioplasty in diabetic patients: the National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94:1818-1825.[Abstract/Free Full Text]
8. Barsness G.W., Peterson E.D., Ohman E.M., et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997;96:2551-2556.[Abstract/Free Full Text]
9. Stein B., Weintraub W.S., Gebhart S.P., et al. Influence of diabetes mellitus on early and late outcome after percutaneous trans-luminal coronary angioplasty. Circulation 1995;91:979-989.[Abstract/Free Full Text]
10. Cohen Y., Raz I., Merin G., Mozes B. Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Am J Cardiol 1998;81:7-11.[Medline]
11. Carrozza J.P., Jr, Kuntz R.E., Fishman R.F., Baim D.S. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993;118:344-349.[Abstract/Free Full Text]
12. Aronson D., Bloomgarden Z., Rayfield E.J. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996;27:528-535.[Abstract]
13. Kuntz R.E. Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma. Circulation 1999;99:847-851.[Free Full Text]
14. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-225.[Abstract/Free Full Text]
15. Brooks M.M., Jones R.H., Bach R.G., et al. Predictors of mortality and mortality from cardiac causes in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial and registry. Circulation 2000;101:2682-2689.[Abstract/Free Full Text]
16. King S.B., III, Lembo N.J., Weintraub W.S., et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 1994;331:1044-1050.[Abstract/Free Full Text]
17. Arom K.V., Flavin T.F., Emery R.W., Kshettry V.R., Janey P.A., Peterson R.J. Safety and efficacy of off-pump coronary artery bypass grafting. Ann Thorac Surg 2000;69:704-710.[Abstract/Free Full Text]
18. Taggart D.P. Respiratory dysfunction after cardiac surgery: effects of avoiding cardiopulmonary bypass and the use of bilateral internal mammary arteries. Eur J Cardiothorac Surg 2000;18:31-37.[Abstract/Free Full Text]
19. Buffolo E., De Andrade C.S., Branco J.N., Teles C.A., Aguiar L.F., Gomes W.J. Coronary artery bypass grafting without cardiopulmonary bypass. Ann Thorac Surg 1996;61:63-66.[Abstract/Free Full Text]
20. Taggart D.P., Browne S.M., Halligan P.W., Wade D.T. Is cardiopulmonary bypass still the cause of cognitive dysfunction after cardiac operations?. J Thorac Cardiovasc Surg 1999;118:414-420.[Abstract/Free Full Text]
21. Arom K.V., Flavin T.F., Emery R.W., Kshettry V.R., Peterson R.J., Janey P.A. Is low ejection fraction safe for off pump coronary bypass operation?. Ann Thorac Surg 2000;70:1021-1025.[Abstract/Free Full Text]
22. Trehan N., Mishra Y.K., Malhotra R., Sharma K.K., Mehta Y., Shrivastava S. Off-pump redo coronary artery bypass grafting. Ann Thorac Surg 2000;70:1026-1029.[Abstract/Free Full Text]
23. Stamou S.C., Dangas G., Dullum M., et al. Beating heart surgery in octogenarians: perioperative outcome and comparison with younger age groups. Ann Thorac Surg 2000;69:1140-1145.[Abstract/Free Full Text]
24. Koutlas T.C., Elbeery J.R., Williams J.M., Moran J.F., Francalancia N.A., Chitwood W.R. Myocardial revascularization in the elderly using beating heart coronary artery bypass surgery. Ann Thorac Surg 2000;69:1042-1047.[Abstract/Free Full Text]

This article has been cited by other articles:

				D. Chu, F. G. Bakaeen, T. K. Dao, S. A. LeMaire, J. S. Coselli, and J. Huh On-Pump Versus Off-Pump Coronary Artery Bypass Grafting in a Cohort of 63,000 Patients. Ann. Thorac. Surg., June 1, 2009; 87(6): 1820 - 1827. [Abstract] [Full Text] [PDF]

				B. Marcheix, F. Vanden Eynden, P. Demers, D. Bouchard, and R. Cartier Influence of Diabetes Mellitus on Long-Term Survival in Systematic Off-Pump Coronary Artery Bypass Surgery Ann. Thorac. Surg., October 1, 2008; 86(4): 1181 - 1188. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF]

				Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF]

				C. Rajakaruna, C. A. Rogers, C. Suranimala, G. D. Angelini, and R. Ascione The effect of diabetes mellitus on patients undergoing coronary surgery: A risk-adjusted analysis J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 802 - 810. [Abstract] [Full Text] [PDF]

				A. H. Lauruschkat, B. Arnrich, A. A. Albert, J. A. Walter, B. Amann, U. P. Rosendahl, T. Alexander, and J. Ennker Prevalence and Risks of Undiagnosed Diabetes Mellitus in Patients Undergoing Coronary Artery Bypass Grafting Circulation, October 18, 2005; 112(16): 2397 - 2402. [Abstract] [Full Text] [PDF]

				J.-S. Choi, K. R. Cho, and K.-B. Kim Does Diabetes Affect the Postoperative Outcomes After Total Arterial Off-Pump Coronary Bypass Surgery in Multivessel Disease? Ann. Thorac. Surg., October 1, 2005; 80(4): 1353 - 1360. [Abstract] [Full Text] [PDF]

				G. Asimakopoulos, A. P. Karagounis, O. Valencia, N. Alexander, M. Howlader, M. A. Sarsam, and V. Chandrasekaran Renal Function After Cardiac Surgery Off- Versus On-Pump Coronary Artery Bypass: Analysis Using the Cockroft-Gault Formula for Estimating Creatinine Clearance Ann. Thorac. Surg., June 1, 2005; 79(6): 2024 - 2031. [Abstract] [Full Text] [PDF]

				C. Kubal, A. K. Srinivasan, A. D. Grayson, B. M. Fabri, and J. A.C. Chalmers Effect of Risk-Adjusted Diabetes on Mortality and Morbidity After Coronary Artery Bypass Surgery Ann. Thorac. Surg., May 1, 2005; 79(5): 1570 - 1576. [Abstract] [Full Text] [PDF]

				J. D. Flaherty and C. J. Davidson Diabetes and Coronary Revascularization JAMA, March 23, 2005; 293(12): 1501 - 1508. [Abstract] [Full Text] [PDF]

				D. Bainbridge, J. Martin, and D. Cheng Off Pump Coronary Artery Bypass Graft Surgery Versus Conventional Coronary Artery Bypass Graft Surgery: A Systematic Review of the Literature Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2005; 9(1): 105 - 111. [Abstract] [PDF]

				F. Kerendi, J. D. Puskas, J. M. Craver, W. A. Cooper, E. L. Jones, O. M. Lattouf, J. D. Vega, and R. A. Guyton Emergency Coronary Artery Bypass Grafting Can Be Performed Safely Without Cardiopulmonary Bypass in Selected Patients Ann. Thorac. Surg., March 1, 2005; 79(3): 801 - 806. [Abstract] [Full Text] [PDF]

				G. J Murphy, R. Ascione, and G. D Angelini Coronary artery bypass grafting on the beating heart: surgical revascularization for the next decade? Eur. Heart J., December 1, 2004; 25(23): 2077 - 2085. [Abstract] [Full Text] [PDF]

				A. K. Srinivasan, A. D. Grayson, and B. M. Fabri On-Pump Versus Off-Pump Coronary Artery Bypass Grafting in Diabetic Patients: A Propensity Score Analysis Ann. Thorac. Surg., November 1, 2004; 78(5): 1604 - 1609. [Abstract] [Full Text] [PDF]

				G. J. Murphy, A. J. Bryan, and G. D. Angelini Hybrid Coronary Revascularization in the Era of Drug-Eluting Stents Ann. Thorac. Surg., November 1, 2004; 78(5): 1861 - 1867. [Abstract] [Full Text] [PDF]

				P. Bergman, L. Hadjinikolaou, G. Dellgren, and J. van der Linden A policy to reduce stroke in patients with extensive atherosclerosis of the ascending aorta undergoing coronary surgery Interactive CardioVascular and Thoracic Surgery, March 1, 2004; 3(1): 28 - 32. [Abstract] [Full Text] [PDF]

				O. Lev-Ran, R. Mohr, K. Amir, M. Matsa, N. Nehser, C. Locker, and G. Uretzky Bilateral internal thoracic artery grafting in Insulin-Treated diabetics: should it be avoided? Ann. Thorac. Surg., June 1, 2003; 75(6): 1872 - 1877. [Abstract] [Full Text] [PDF]

				R Ascione and G.D Angelini OPCAB surgery: a voyage of discovery back to the future Eur. Heart J., January 2, 2003; 24(2): 121 - 124. [Full Text] [PDF]

				R. Ascione, M. Caputo, and G. D. Angelini Off-pump coronary artery bypass grafting: not a flash in the pan Ann. Thorac. Surg., January 1, 2003; 75(1): 306 - 313. [Abstract] [Full Text] [PDF]

				R. Salenger, J. S. Gammie, and T. J. Vander Salm Postoperative Care of Cardiac Surgical Patients Card. Surg. Adult, January 1, 2003; 2(2003): 439 - 469. [Full Text]

				M. J. Mack and F. G. Duhaylongsod Through the open door! Where has the ride taken us? J. Thorac. Cardiovasc. Surg., October 1, 2002; 124(4): 655 - 659. [Full Text] [PDF]

				R. Ascione, S. Al-Ruzzeh, K. Amer, and G. D Angelini Subsystem organ function during coronary surgery Perfusion, July 1, 2002; 17(4): 295 - 303. [Abstract] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Mitchell J. Magee Todd M. Dewey Tea Acuff James R. Edgerton Michael J. Mack Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Magee, M. J. Articles by Mack, M. J. Search for Related Content PubMed PubMed Citation Articles by Magee, M. J. Articles by Mack, M. J. Related Collections Coronary disease Related Article